title: Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk.
abstract: A number of studies were performed to assess the association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and susceptibility to type 2 diabetes (T2DM). However, the results were inconsistent and inconclusive. In the present study, the possible association was investigated by a meta-analysis. Eligible articles were identified for the period up to June 2013. Pooled odds ratios (OR) with 95% confidence intervals (CI) were appropriately derived from random-effects models or fixed-effects models. Fourteen case-control studies with a total of 2487 cases and 3538 controls were eligible. In recessive model, PAI-1 4G/5G polymorphism was associated with T2DM risk (OR = 1.23; 95% CI 1.07-1.41; P = 0.004). In the subgroup analysis by ethnicity, a significant association was found among Asians (OR = 1.27; 95% CI 1.08-1.51; P = 0.005). This meta-analysis suggested that PAI-1 4G/5G polymorphism may be associated with T2DM development.
authors.affiliation: Department of Gerontology Endocrinology, Guangzhou First People's Hospital, Guangzhou Medical University Guangzhou 510180, Guangdong, China.
authors.forename: Luqian
authors.initials: L
authors.lastname: Zhao
authors.forename: Ping
authors.initials: P
authors.lastname: Huang
keywords: Type 2 diabetes; meta-analysis; plasminogen activator inhibitor-1; polymorphism
references.citation: Diabetes. 2004 Feb;53(2):336-46
references.pmid: 14747283
references.citation: Clin Chim Acta. 2008 Oct;396(1-2):18-22
references.pmid: 18619429
references.citation: Diabetes Care. 2003 Mar;26(3):917-32
references.pmid: 12610059
references.citation: Cytokine. 2012 Dec;60(3):849-55
references.pmid: 23017230
references.citation: Obesity (Silver Spring). 2006 May;14(5):753-8
references.pmid: 16855181
references.citation: Di Yi Jun Yi Da Xue Xue Bao. 2004 Aug;24(8):904-7
references.pmid: 15321757
references.citation: Arteriosclerosis. 1988 Jan-Feb;8(1):68-72
references.pmid: 2449156
references.citation: Arterioscler Thromb Vasc Biol. 1999 May;19(5):1361-5
references.pmid: 10323791
references.citation: J Biol Chem. 2006 Oct 27;281(43):32796-805
references.pmid: 16931518
references.citation: PLoS One. 2012;7(7):e42062
references.pmid: 22844542
references.citation: Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1104-17
references.pmid: 11451738
references.citation: Circulation. 2006 Apr 11;113(14):1753-9
references.pmid: 16585388
references.citation: Stat Med. 2005 May 15;24(9):1291-306
references.pmid: 15568190
references.citation: Am J Clin Nutr. 2005 Mar;81(3):555-63
references.pmid: 15755822
references.citation: Thromb Haemost. 2006 Dec;96(6):731-7
references.pmid: 17139366
references.citation: Nature. 2001 Dec 13;414(6865):782-7
references.pmid: 11742409
references.citation: Kidney Int. 1998 Nov;54(5):1659-69
references.pmid: 9844142
references.citation: Br J Haematol. 2001 Dec;115(3):491-506
references.pmid: 11736929
references.citation: J Biomed Biotechnol. 2012;2012:234937
references.pmid: 22577291
references.citation: Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2209-15
references.pmid: 16825598
references.citation: Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1851-5
references.pmid: 7892190
references.citation: FASEB J. 2001 Aug;15(10):1840-2
references.pmid: 11481248
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563